タイロカルシトニン: 甲状腺のヒポカルセミク・ヒポフォスファテミク原理

P F HIRSCH, E F VOELKEL, P L MUNSON

Science (New York, N.Y.)

|October 16, 1964

まとめ

研究者らは,豚の甲状腺から新しい因子を精製し,ネズミの血清カルシウムと無機リン酸のレベルを大幅に低下させた. このポリペプチドは,チロキシンなどの既知の甲状腺ホルモンとは異なる.

科学分野:

エンドクリノロジーエンドクリノロジー
バイオケミストリーバイオケミストリー
ミネラルメタボリズム

背景:

甲状腺は代謝を調節するホルモンを産生することが知られている.
タイロキシンやトリヨドチロニンなどの甲状腺ホルモンは,代謝制御に不可欠です.
鉱物ホメオスタシスに影響を与える他の甲状腺因子の存在が仮定されている.

研究の目的:

血清カルシウムと無機リン酸のレベルに影響を与える豚甲状腺からの因子を分離し,特徴づけること.
この因子が,既知の甲状腺ホルモンと関連しているかどうかを判断する.

主な方法:

0.1N HCl.を使用した豚の甲状腺の抽出.
500倍濃度のプロセスを通して活性因子の浄化.
バイオケミカル分析により,その因子の性質と,チロキシンとトリヨドチロニンとの違いを判定する.

主要な成果:

ネズミの血清カルシウムと無機リン酸を低下させることができる因子が,成功裏に浄化されました.
精製された因子は,甲状腺抽出物から500倍濃縮された.
この因子はポリペプチドとして特定され,チロキシンとトリヨドチロニンとは異なることが実証されました.

結論:

豚の甲状腺には,血清カルシウムと無機リン酸のレベルを積極的に低下させるポリペプチド因子が含まれています.
この新たに精製された因子は,既定の甲状腺ホルモンとは異なる新しいホルモンまたは調節物質を表しています.
この低カルシウム/低リン酸化因子の正確な作用機構と生理学的役割を明らかにするために,さらなる研究が必要である.

キーワード:

血液は,血液である.血液のリン酸塩はカルシウムカルシウム化学,分析的化学について実験実験室での研究低カルセミア症候群 (HYPOCALCEMIA) とは,高カルセミア症候群 (HYPOCALCEMIA) とは,高カルセミア症候群 (HYPOCALCEMIA) とは "豚"とは,豚のことです.タイロカルシトニンニン (THYROCALCITONIN) とは甲状腺腺甲状腺は,甲状腺に組織抽出物組織抽出物

さらに関連する動画

06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

03:05

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

関連する概念動画

01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...

01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...

01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...

01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...

01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...

関連する実験動画